AI & Diagnostics Software

Intuitive Surgical, Inc. is a global leader in robotic-assisted surgical systems and digital health solutions. The company manufactures the da Vinci family of robotic surgery platforms, which enable minimally invasive surgical procedures across multiple specialties including general surgery, urology, gynecology, cardiothoracic, and orthopedics. Core product lines include the da Vinci 5 (advanced integrated robotic platform with surgeon console and patient cart), the da Vinci SP (single-port robotic system for new surgical approaches), and the Ion robotic bronchoscopy system for lung cancer diagnosis and biopsy. Intuitive also manufactures da Vinci instruments and accessories designed for precision and ergonomic control. Beyond hardware, the company provides digital solutions including My Intuitive (data analytics and insights platform for surgical teams) and SimNow (surgeon training and simulation software). The company operates a global infrastructure with expanded direct operations in Europe and provides 24/7 service and support. Intuitive's systems are used in hospitals worldwide for minimally invasive surgery, and the company has established itself as the market leader in robotic-assisted surgical technology since its founding in 1995. The platform emphasizes surgeon autonomy, precision, and patient outcomes through advanced visualization and control systems.

Medasense Biometrics Ltd. is an Israel-based medtech company specializing in AI-driven nociception monitoring to quantify pain response and optimize analgesia in clinical settings. The company's proprietary NOL® technology analyzes physiological signals to help clinicians personalize pain treatment, reduce opioid use, and prevent postoperative pain. The FDA-authorized PMD-200™ platform is designed for critical care applications including anesthesia and surgery, providing real-time visualization of patient pain levels. Medasense's pipeline includes NOLedge™, which extends pain insights to clinic and home care settings. The company addresses the global pain management crisis through non-invasive quantification of pain responses, supporting healthcare providers with clinical evidence, education via Medasense Academy, and collaborations with major OEMs including Medtronic, Philips, Mindray, and Nihon Kohden. Applications span intraoperative monitoring, postoperative pain prevention, and emergency care settings.

Conductive Technologies Inc. (CTI) is a contract manufacturer specializing in printed electronics and biosensors for the medical device and industrial markets. Founded in 1970 and based in York, Pennsylvania, CTI operates a 110,000 sq. ft. facility with approximately 61 employees and generates $15.4 million in annual revenue. The company holds FDA compliance and ISO 13485 (medical devices) and ISO 9001 certifications, supporting full medical device project development from conception through FDA clearance. CTI's core competencies include electrochemical sensors, biosensors, flexible circuits, and membrane switches. The company manufactures disposable glucose test strips, multiplexed point-of-care diagnostic sensors, wearable devices, and biochips/microfluidics. Manufacturing capabilities include precision laser ablation, fine-line screen printing, and flexible printed circuitry with diverse inks and materials. CTI offers design innovation, development services, and post-commercialization collaboration, particularly for next-generation disposable diagnostic biosensors and Phase Zero Sensors for early-stage biochemical assay development. The structured development process ensures products meet customer requirements and market competitiveness.

RedDrop Dx is a Fort Collins-based medical device company specializing in next-generation capillary blood sampling systems for remote and at-home diagnostics. Their flagship product, RedDrop One, is an FDA-cleared device utilizing microneedles to enable virtually pain-free whole blood and plasma collection with minimal discomfort. The device collects up to 1mL of capillary blood in a single click with 97% clinical success rate. RedDrop One is designed for scalability with automation-ready 1mL tubes optimized for high-throughput laboratory integration, making it suitable for home health, point-of-care testing, decentralized clinical trials, and research applications. The company addresses traditional phlebotomy challenges by providing intuitive, reliable blood sampling infrastructure that improves patient experience while maintaining sample integrity and volume consistency.

CyberLogic develops FDA-approved ultrasound bone densitometry devices and advanced ultrasound simulation software. The company's UltraScan 650 is the first and only FDA-approved ultrasound bone densitometer that measures bone mineral density (BMD) using patented NTD technology, delivering DXA-equivalent accuracy without radiation exposure. The device operates in under 10 seconds, is portable and USB-powered, making it suitable for clinical osteoporosis screening and monitoring in primary care, women's health, and population screening programs. CyberLogic also offers the Wave-series software (Wave2000, Wave2500, Wave3000) for high-fidelity 2D and 3D viscoelastic wave modeling in biomedical imaging, tissue characterization, nondestructive testing, transducer design, and material characterization. Backed by 30+ years of research and peer-reviewed validation, CyberLogic serves hospitals, universities, research labs, and engineers worldwide.

BrightInsight is a cloud-based digital health platform company serving biopharma and medtech organizations. The company specializes in developing and maintaining regulated digital health solutions, including Software as a Medical Device (SaMD), companion patient apps, connected medical devices, clinical algorithms, and healthcare provider interfaces. The BrightInsight Platform provides a configurable, enterprise-grade solution that enables faster time-to-market while ensuring compliance with global regulatory standards. The company has delivered 14 SaMD solutions across 11 therapy areas and partners with 6 of the top 10 biopharma firms. Core capabilities include real-world data collection, patient engagement tools, clinical outcome analytics, and disease management solutions. BrightInsight addresses the critical business need for regulated digital health deployment, helping life sciences companies differentiate therapies, improve patient adoption and retention, and unlock real-world evidence from connected digital health ecosystems.

Sebia Autoimmune & Infectious Diseases (formerly ZEUS Scientific) is a US-based in vitro diagnostic (IVD) company with 45+ years of clinical diagnostics expertise. Founded in 1976 and acquired by Sebia in October 2022, the company develops, manufactures, and markets high-quality immunoassays for autoimmune disorders and infectious diseases. ZEUS Scientific offers a portfolio of over 125 FDA-cleared assays utilizing Indirect Fluorescent Antibody (IFA) and Enzyme Immunoassay (EIA) technologies. Key products include automated IFA slide processing systems and digital immunofluorescence imaging solutions. The company provides comprehensive contract manufacturing, OEM partnerships, and custom diagnostic solutions. With deep expertise in immunofluorescence imaging, flow cytometry, and clinical protein electrophoresis, ZEUS Scientific supports hospital laboratories, clinical research organizations, and diagnostic manufacturers globally with workflow automation and quality assurance.

Medicalgorithmics S.A. is a Warsaw-based, publicly listed (GPW) medical technology company founded in 2005, specializing in AI-powered, noninvasive cardiac diagnostic solutions. The company develops and manufactures a comprehensive suite of ECG monitoring devices and cloud-based software platforms that leverage advanced artificial intelligence to detect, classify, and analyze cardiac arrhythmias. Key product offerings include PocketECG (full-disclosure mobile cardiac telemetry with rich diagnostic reporting), Kardiobeat.ai (wearable 24–18 day Holter monitor with AI-driven analysis), DeepRhythm Platform (DRP) – a hardware-agnostic cloud ECG platform with FDA clearance and Health Canada licensing – DeepRhythmAI (DRAI) for rapid arrhythmia detection across third-party devices, and Virtual Cardiac Stress Test (VCAST), an advanced CT-based diagnostic tool for coronary artery assessment. All core products carry FDA 510(k) clearance, EU MDR certification, and Health Canada approval. The company serves cardiologists, healthcare systems, and clinical research organizations across North America, Europe, and Asia-Pacific, with an extensive annotated heartbeat library supporting over 100 arrhythmia types. Medicalgorithmics also provides R&D services, clinical trial support, and scientific research partnerships focused on cardiovascular disease diagnosis.

Alveo Technologies is a molecular diagnostics company specializing in decentralized, point-of-need pathogen detection platforms. The company's flagship be.well platform integrates sample preparation, nucleic acid amplification, and real-time electrical sensing detection into a palm-sized, portable analyzer delivering results in under one hour. Applications span acute respiratory infections (COVID-19, influenza), avian influenza in poultry, plant pathogens in agriculture, and environmental/wastewater surveillance. The platform is cloud-connected, smartphone-guided, and designed for use by non-specialized personnel in field settings. Alveo serves livestock, food & beverage, companion animal, and public health sectors, with partnerships including Royal GD (Netherlands) for veterinary diagnostics and deployment across Egypt for nationwide avian flu surveillance.

CognifiSense is a Silicon Valley-based company specializing in FDA-cleared Virtual Reality Neuropsychological Therapy (VRNT) for chronic pain management. The platform uses immersive VR technology to retrain neural pathways and break maladaptive pain cycles, enabling patients to achieve lasting relief without medication or invasive treatments. VRNT combines movement, breathing, and cognitive exercises delivered through VR headsets to help patients visualize and process their pain differently, reducing pain intensity and restoring mobility. The therapy is personalized, non-invasive, drug-free, and can be delivered at home with insurance coverage. Clinical data demonstrates 80% of patients experience meaningful relief. CognifiSense serves both patients directly and healthcare providers through a B2B2C model.

Epicore Biosystems is a digital health and biomedical wearables company specializing in sweat-sensing microfluidic technology. The company develops non-invasive biowearable devices that analyze sweat biomarkers—including electrolytes, metabolites, nutrients, and stress markers—to provide real-time physiological insights. Epicore's proprietary sweat microfluidic sensing platform integrates cloud analytics for personalized health monitoring and decision support. The company's primary solutions target three market segments: industrial safety (workplace hydration and heat stress monitoring), sports and fitness (performance optimization and recovery tracking), and clinical research (biomarker discovery and FDA-registered data collection systems). Epicore's Connected Hydration platform delivers continuous monitoring with real-time alerts, and its Discovery Patch provides laboratory-grade sweat analysis for research applications. The company has established partnerships with major enterprises including Chevron, PepsiCo, Gatorade, and the U.S. Air Force Research Laboratory, deploying solutions across energy, construction, and professional sports sectors.

UC-Care develops innovative, fully automated end-to-end solutions for prostate cancer diagnosis and treatment, specifically MRI-ultrasound fusion-guided biopsy and focal therapy procedures. The company's core offering integrates real-time patient motion compensation and automated image processing to enable precise lesion targeting and specimen management. UC-Care's solutions—including the Navigo 4D fusion navigation system, SmartBx biopsy management platform, and FusionStudio DICOM contouring software—are designed to adapt seamlessly to existing clinical workflows in physician practices, ASCs, and hospital settings. The technology delivers improved cancer detection rates (25% increase documented), maintains diagnostic precision despite patient movement, and provides cost-effective fusion-guided biopsy capabilities previously limited to specialized centers. Products are developed with deep understanding of physician and technician realities to minimize workflow disruption while maximizing procedural accuracy and reimbursement alignment.

Alleye is a digital health platform specializing in early detection and monitoring of retinal diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME). The Alleye app enables patients to regularly test their visual performance via mobile device using a proprietary test that detects vision deterioration before it becomes clinically apparent. The platform includes treatment tracking for injection-based therapies, appointment management, and health status surveys. Healthcare providers (eye doctors, opticians, pharmacists) access the alleye.io management portal to oversee patient data and treatment outcomes. Clinical evidence demonstrates that patients using Alleye achieve better visual outcomes, improved treatment efficiency, and enhanced patient engagement in their eye health management.

iTonic is an AI-powered home health platform that serves as the operating system for connected care across patients, families, and healthcare providers. The platform integrates smart medication management, remote patient monitoring, and an emotionally-intelligent AI companion (SAVi) that delivers voice-enabled check-ins, personalized health coaching, and behavioral engagement. The system includes family and provider dashboards offering real-time visibility and transparency across the circle of care. iTonic targets seniors, veterans, Medicare/Medicaid populations, and senior living facilities, with demonstrated clinical outcomes including 30% reduction in hospital readmissions, 40% higher patient engagement, and 10% improvement in medication adherence. The modular, interoperable platform is designed to integrate with existing medical devices and healthcare systems while prioritizing intuitive, human-centered user experience across intergenerational care teams.

AIVITA Biomedical is a biotechnology company specializing in personalized vaccines and autologous cell-based therapies for cancer treatment, infectious disease prevention, and vision loss. The company employs a pan-antigenic approach targeting all neoantigens in cancer vaccines to overcome tumor mutation resistance. Lead product AV-GBM-1 is an autologous dendritic cell immunotherapy in Phase III trials for glioblastoma multiforme. Additional pipeline includes AV-MEL-1 for metastatic melanoma, a personalized multi-pathogen vaccine kit for emerging infectious disease prevention, and stem cell therapies for retinal degeneration. AIVITA's proprietary autologous cell therapy platform and stem cell differentiation expertise enable safe and economical manufacturing of personalized immunotherapeutic solutions across oncology, infectious disease, and ophthalmology indications.

Lonza is a Swiss multinational contract development and manufacturing organization (CDMO) founded in 1897, headquartered in Basel. The company operates 30+ development and manufacturing sites globally and employs approximately 20,000 colleagues across five continents. As the pioneer and world leader in the CDMO industry, Lonza specializes in biopharmaceutical manufacturing and offers integrated services across biologics development, mammalian cell culture systems, small molecules and highly potent active pharmaceutical ingredients (HPAPIs), bioconjugates, cell and gene therapies (CGT), advanced mRNA technologies, and specialized modalities. The company also manufactures pharmaceutical capsules and health ingredients for nutraceutical applications. Lonza provides end-to-end support from drug development through manufacturing and commercialization, serving major pharmaceutical and biotechnology customers globally. Notable partnerships include production collaboration with Moderna for COVID-19 vaccine manufacturing.

ClariMed, Inc. is a global regulatory and human factors consulting firm headquartered in Chadds Ford, Pennsylvania, with offices across North America and Europe. Founded in 2022, the company specializes in user-centered design, human factors engineering, and quality management solutions for medical devices, combination products, and in-vitro diagnostics. ClariMed provides comprehensive end-to-end services including user needs assessments, contextual inquiries, human factors validation testing, regulatory compliance support, Quality Management System (QMS) implementation, UI/UX design, cybersecurity solutions, and strategic advisory services. The firm's multidisciplinary team brings expertise in human factors, industrial design, biomedical engineering, psychology, and quality engineering. ClariMed is ISO 13485:2016 certified and offers flexible engagement models—project-based consulting, embedded resources, retainer, and end-to-end support—to help MedTech and pharmaceutical companies accelerate time to market while ensuring safety, efficacy, and user satisfaction.

Converge Medical Technology is a healthcare services and medical device company specializing in evidence-based solutions for chronic musculoskeletal pain, particularly low back and neck pain. The company develops smart devices, digital therapeutics, and home-based care programs delivered nationwide to patients and supported by multidisciplinary clinical oversight. Core offerings include the AXIS cervical strengthening device, MedX lumbar extension system, digital therapeutic apps, and ThermaZone thermal therapy for worker's compensation recovery. All programs emphasize home convenience, AI-driven treatment adherence monitoring, and pain reduction without surgery. Prescription-based delivery model targets injured workers, military veterans, post-surgical patients, and individuals with chronic pain lasting beyond 4 weeks. Clinical outcomes documented across 75+ peer-reviewed research articles demonstrate improvements in spinal range of motion, core strength, and functional disability reduction.

CaviSense is a dental diagnostics platform that detects early-stage cavities in real time using patented pH-sensing technology developed in collaboration with Harvard and Tufts University. The at-home detection and monitoring device identifies cavities while still reversible—before traditional diagnostics catch them—enabling early intervention and preventive care. CaviSense serves both dental practices seeking efficient patient monitoring and individual consumers seeking proactive oral health management. The device delivers results in approximately 10 seconds and supports remineralization monitoring and biofilm pH analysis to guide clinical decision-making and patient behavior change.

Preco, LLC is a designer and manufacturer of precision automated processing systems with over 50 years of industry experience. The company specializes in high-speed, high-accuracy laser processing and die cutting equipment for medical device manufacturing, flexible packaging, advanced energy, aerospace, and electronics applications. Preco offers two primary service models: contract manufacturing services (laser cutting, scoring, perforating, welding, cladding, and heat treating) and capital equipment sales (laser systems, rotary die cutting equipment, and flat bed die cutting systems). The company provides comprehensive support including applications development, process development, pilot production, and full-scale manufacturing. With facilities in Wisconsin (laser processing and contract manufacturing) and Kansas (rotary and flat bed die cutting), plus a subsidiary in Sweden and global service network, Preco serves as a complete solutions partner for enterprises requiring precision material processing capabilities.

Luminopia Inc. is an FDA-cleared digital therapeutics company specializing in VR-based treatment for pediatric amblyopia (lazy eye) in children aged 4–12. The company delivers its prescription-only Luminopia software through commercially available VR headsets, enabling patients to receive binocular vision therapy while watching curated TV content instead of traditional patching. The treatment regimen requires one hour daily, six days weekly, with clinical trials demonstrating significant vision improvement within 4–12 weeks. Luminopia is prescribed by ophthalmologists, optometrists, and orthoptists; the company handles fulfillment, patient support, and compliance monitoring. Designed for at-home use alongside corrective lenses, Luminopia achieved 94% parental preference over conventional patching and demonstrated 85% median treatment completion rates, addressing the long-standing compliance challenges in amblyopia management.

CYBERDYNE USA Inc. is a medical robotics and cybernics innovation company developing integrated cyber-physical systems for healthcare and rehabilitation. Founded on the cybernics academic framework—fusing neuroscience, robotics, AI, and engineering—the company manufactures wearable robotic exoskeletons (HAL series) for clinical rehabilitation, mobility assistance, and caregiver support. The HAL Lower Limb Type and Single Joint Type devices enable neuroplastic improvement in gait and joint function through active human-robot interaction. Beyond medical devices, CYBERDYNE produces autonomous hospital robots for cleaning, disinfection, and material transport, alongside communication assistive systems (Cyin, AcousticX) for patients with severe mobility or speech impairments. The company pursues clinical implementation globally through strategic partnerships with universities and healthcare institutions, publishing peer-reviewed research on cybernics treatment outcomes.

AcroCyte Therapeutics Inc. develops the R³CE® (Rapid, Reproducible, Rare Cell 3D Expansion) platform—an FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens including circulating tumor cells, needle biopsies, and frozen tissues into functional 3D organoids within days. The company offers R³CE® culture plates and specialized media for research and clinical applications, alongside the Onco-REAL™ clinical diagnostic service providing comprehensive functional analysis from liquid biopsies to support oncology treatment decisions. AcroCyte's technology platform enables drug developers to accelerate preclinical screening, clinicians to deliver personalized ex vivo drug sensitivity testing, and researchers to create customized 3D models that replicate physiological conditions. The platform eliminates reliance on traditional cell lines and animal models, addressing key limitations in reproducibility, speed, and sample efficiency for precision medicine applications across oncology, regenerative medicine, and drug discovery.

Vassol, Inc. develops NOVA (Noninvasive Optimal Vessel Analysis), an advanced 3D blood flow analytics and imaging software platform for quantitative hemodynamic analysis of cerebral vasculature. NOVA integrates with standard MRI systems—specifically Time-of-Flight MRA and 2D phase-contrast magnetic resonance imaging—to generate three-dimensional vascular models and quantify intracranial blood flow without contrast agents or radiation exposure. The platform is vendor-neutral, PACS-compatible, and features automated processing with patented algorithms for perpendicular scan plane prescription. Clinically validated over 20+ years, NOVA serves neuroradiologists and stroke specialists for diagnosis, treatment planning, and post-intervention assessment of cerebrovascular conditions including carotid stenosis, vertebrobasilar disease, arterial dissection, aneurysm management, and moyamoya disease. An NIH study demonstrated NOVA qMRA® as a robust, independent predictor of recurrent stroke risk.

Head Health Company, Ltd. is a leader in head health and safety solutions, leveraging internationally-patented wearable technology to improve patient outcomes. The company develops clinical-grade wearable medical devices that use biometric sensors placed on the head—one of the body's richest sensing areas—for continuous patient monitoring and remote healthcare management. Their technology focuses on core vitals collection, correlation, and visualization with AI-driven insights to provide real-time, predictive health monitoring. Primary market segments include patient temperature management for surgical procedures, EMS/trauma care, and digital health/AI-integrated remote monitoring. The wearable platform is designed to integrate with healthcare systems for enhanced patient care and valuable clinical insights.

DARI Motion is an FDA-cleared markerless motion capture technology platform specializing in full-body biomechanical analysis for clinical, sports medicine, and wellness applications. The system delivers validated 3D kinematic and kinetic data within five minutes, with cloud-enabled insights in under 20 seconds. DARI Motion's patented technology integrates Captury motion capture software to provide comprehensive human motion analysis including performance scoring, mobility assessment, alignment evaluation, balance/sway analysis, and force/torque measurement across all major joints and limbs. The platform enables injury prevention screening, rehabilitation progress tracking, and performance benchmarking for athletes and patients. Applications span hospital clinics, orthopedic practices, sports training facilities, and corporate wellness centers. Trusted by organizations including Hospital for Special Surgery, Steadman Clinic, and Exos, DARI Motion empowers clinical decision-making and accelerates patient recovery outcomes through objective, repeatable biomechanical data collection.

HANS BIOMED CORP. is a global biotechnology company specializing in medical devices and cosmeceuticals, headquartered in Seoul with UK & European operations. The company focuses on minimally invasive aesthetic solutions and biomedical skincare products backed by R&D innovation and regulatory certifications (CE and FDA approval). Primary product lines include MINT™ PDO threads for non-surgical facial rejuvenation and tissue regeneration, microcannula delivery systems, and Klárdie cosmeceutical skincare and skinbooster formulations utilizing nano-formulation and stem cell culture medium technology. The company serves aesthetic practitioners and medical professionals across Europe, North America, and Asia with a commitment to safety, quality, and science-based innovation in anti-aging treatments and skin elasticity enhancement.

Zymo Research Corp is a biotechnology company founded in 1994, specializing in molecular biology tools and services. Based in Irvine, California, the company focuses on DNA and RNA purification, epigenetics, microbiomics, and next-generation sequencing (NGS). With approximately 116 employees and annual revenue of $22.8 million, Zymo Research has established a global presence with six international facilities and a wide distribution network. The company emphasizes simplicity in science through its philosophy of 'The Beauty of Science is to Make Things Simple.' Zymo Research prioritizes customer feedback to develop innovative technologies that enhance scientific workflows. Their product offerings include sample preservation solutions (DNA/RNA Shield), comprehensive sequencing and analysis services, advanced purification technologies (Direct-zol, ZymoPURE, Quick-DNA/RNA kits), epigenetics tools (EZ DNA Methylation, bisulfite sequencing), and microbiome standards. Zymo serves academia, healthcare, and industry globally, collaborating with institutions to support scientific research and innovation.

Axolo Health develops TBRx, an Extended Reality (XR) therapy platform combining virtual and augmented reality to treat phantom limb pain and support neurorehabilitation after amputation. The clinically-backed, physician-developed system delivers customized, immersive therapeutic exercises that help retrain the brain, reduce pain without opioids, and improve mobility and quality of life. TBRx is offered to both individual patients and healthcare providers (physiatrists, orthopedic surgeons, prosthetists, occupational therapists) for integration into rehabilitation programs.

Medical Predictive Science Corporation (MPSC) develops the HeRO (Heart Rate Characteristics) System, an FDA-cleared predictive monitoring platform for neonatal intensive care. HeRO uses proprietary algorithms to detect subtle irregularities in heart rate variability that precede patient deterioration by hours to days, providing early warning for sepsis, necrotizing enterocolitis (NEC), urinary tract infections, meningitis, respiratory decompensation, brain pathology, and mortality risk. The technology analyzes cytokine-driven changes in autonomic nervous system response during early infection and inflammatory events, generating hourly risk scores for infection in the subsequent 24 hours. Clinical evidence from the largest randomized controlled trial in neonatology (3,003 very low birthweight infants) demonstrated a 22% reduction in overall mortality and 40% reduction in mortality among infected patients, with average diagnostic timing improvement of 18+ hours—enabling earlier antibiotic intervention before systemic progression. HeRO operates as a standalone bedside monitor or embedded module within compatible central monitoring systems.

EpiWatch is an FDA-cleared, prescription-based mobile health platform that delivers real-time tonic-clonic seizure detection and alerting via Apple Watch and iPhone. The AI-powered application runs passively on wearable devices to monitor seizure activity and provides immediate alerts to caregivers when critical events occur, enabling rapid intervention and reducing the risk of Sudden Unexpected Nocturnal Death in Epilepsy (SUDEP). Designed for both pediatric and adult patients with epilepsy, EpiWatch integrates with family sharing and caregiver contact systems, requiring cellular or Wi-Fi connectivity for continuous monitoring. Available by prescription only in the United States at a monthly subscription fee, the platform empowers patients with independence while providing caregivers actionable intelligence during life-threatening events.

Medihub Co., Ltd. is a South Korean medical device manufacturer specializing in automated injection systems and digital injection technology. The company develops advanced injection devices including the i-JECT ST and i-JECT One platforms, designed to enhance safety, comfort, and procedural ease for both patients and healthcare professionals. Medihub leverages digital control algorithms and artificial intelligence integration to optimize injection procedures across clinical and educational settings. The company is positioning itself as a global leader in the automated injection device sector, with applications spanning conventional medicine and traditional medicine (herbal acupuncture). Medihub holds multiple patents and actively pursues clinical research partnerships to advance injection technology and expand market presence.

HeraMED Ltd is a Melbourne-based medical data and technology company specializing in AI-powered digital health solutions for women across their life stages, with particular focus on maternity care. The company's flagship HeraCARE platform provides remote monitoring, telehealth, customizable care plans, educational content, and AI-driven clinical decision support. The FDA-cleared HeraBEAT device enables home-based fetal and maternal heart rate monitoring. HeraMED's integrated solution combines an AI Clinician Dashboard for care providers (featuring ambient scribing, structured documentation, and centralized vitals/alerts) with an AI Virtual Companion patient app that delivers personalized education, symptom triage, and proactive engagement. The platform addresses fragmented women's healthcare by enabling continuous longitudinal monitoring across fertility, pregnancy, postpartum, menopause, and chronic conditions. Clinically validated through partnerships with Mayo Clinic and Broward Health, HeraMED demonstrates measurable outcomes including 50% reduction in postpartum readmissions, earlier detection of gestational hypertension, improved medication adherence, and reduced no-show rates. The solution serves maternity care deserts and underserved markets in Australia and the United States.

Anhui Deepblue Medical Technology Co., Ltd. is a leading in vitro diagnostic (IVD) reagent manufacturer established in 2010 and headquartered in Hefei High-Tech Zone, Anhui, China. Specializing in R&D, manufacturing, and global marketing of rapid diagnostic test kits and biological raw materials, the company serves gynecological, family planning, and digestive medicine markets. Core product lines include HCG pregnancy test strips, LH ovulation test strips, fecal occult blood tests, IGFBP-1 PROM test kits, bacterial vaginosis tests, PCT test kits, infectious disease rapid tests, respiratory disease tests, tumor marker tests, drug-of-abuse tests, and virus sampling tubes (VTM). The company maintains ISO 13485:2016 and MDSAP certifications, with CE0123, CE1434, and UK MHRA approvals. Products are distributed across nearly 100 countries including Europe, North America, South America, the Middle East, and Southeast Asia. Deepblue Medical offers OEM/ODM services, advanced automation production capabilities, and comprehensive after-sales support for hospital, clinical laboratory, and point-of-care diagnostic applications.

Surge Motion is a digital physical therapy platform that enables objective assessment and remote monitoring of balance, gait, mobility, and functional strength. The FDA-listed Aspire Motion suite uses wearable-based biomechanical analysis and quantitative movement sensing to measure body dynamics with clinical research-grade accuracy. The platform serves physical therapists, rehabilitation clinicians, and home-care providers with tools for patient evaluation, progress tracking, and evidence-based exercise prescription. Core applications include balance and vestibular rehabilitation, fall-prevention therapy, and remote therapeutic monitoring for aging populations and patients recovering from injury or neurological conditions. The technology extracts actionable clinical insights from complex kinematic data, making objective movement analysis accessible in real-world settings without expensive laboratory equipment.

623 Medical is a medical technology company specializing in nüm®, a sterile, single-patient-use topical anesthetic spray designed to reduce pain and anxiety associated with needle-related procedures. The fast-acting vapocoolant spray provides rapid numbing to the skin prior to vaccinations, blood draws, IV starts, injections, port access, biopsies, and minor surgical procedures. nüm eliminates cross-contamination risk through single-patient use and sterility assurance, while offering immediate onset without messy creams or loud devices. The product is particularly valuable for pediatric patients and adults with injection phobias, improving procedural comfort and patient satisfaction across healthcare settings.

mTrigger is a biofeedback device manufacturer specializing in wireless surface electromyography (sEMG) technology for physical therapy, occupational therapy, athletic training, pelvic floor therapy, and speech-language pathology. The company's flagship product suite provides real-time visual biofeedback of muscle activation, enabling clinicians to quantify muscle deficits, reinforce proper movement patterns, and track patient progress. By gamifying the rehabilitation experience through interactive mobile applications, mTrigger enhances patient engagement and compliance while improving neuromuscular outcomes across diverse clinical populations, including post-operative shoulder and knee patients, athletes, and individuals with motor control dysfunction. The system is designed by rehabilitation professionals for clinical use in outpatient therapy settings and home-based programs.

moveUP is a Belgium-based digital health SaaS platform founded in 2015, specializing in AI-driven digital therapeutics and remote patient monitoring solutions. The company delivers clinically validated digital patient support programs that enhance therapy compliance, automate triage, and enable real-time provider collaboration across multiple therapeutic domains. Core offerings include patient-facing mobile apps for education and treatment adherence, intuitive provider dashboards with integrated communication tools, automated clinical workflows, and real-world data collection and analytics capabilities. The moveUP Therapy platform utilizes adaptive AI algorithms that monitor over 400 patient data points to personalize pre- and post-hospital care journeys. The company serves hospitals, health systems, pharmaceutical manufacturers, and medical device companies primarily in orthopedics, bariatrics, oncology, cardiology, respiratory, neurology, dermatology, and hematology. Clients include major hospital networks (UZ Leuven, UZ Gent, Pius Hospital) and pharmaceutical partners (Sanofi, Novartis, AstraZeneca, Amgen). Platform is FDA-registered, CE-marked, ISO 13485 and ISO 27001 certified, GDPR compliant, and reimbursed in EU markets.

Alimetry Ltd is a medtech company specializing in advanced wearable medical devices and AI-driven diagnostics for gastrointestinal disorders. Founded in 2019 by Dr. Greg O'Grady and Dr. Armen Gharibans, the company operates from Auckland, New Zealand with expanded operations in the US, serving over 2,500 patients. The flagship product, Gastric Alimetry™, is an FDA-cleared and CE-marked non-invasive diagnostic system that performs Body Surface Gastric Mapping (BSGM) to record gastric electrophysiology over a 4.5-hour session. This technology aids clinicians in diagnosing complex gastric disorders including gastroparesis and motility issues by providing objective, data-driven insights into gastric function and electrophysiology. The system features an adhesive electrode array placed on the patient's abdomen, integrated symptom logging via mobile app, and an auto-generated diagnostic report with validated normative values. Alimetry Care, a developing home-monitoring wearable and remote care service, aims to expand accessibility for patients with chronic GI symptoms and supports personalized medicine approaches.

The Jacobs Institute is a not-for-profit vascular medical technology innovation center located in Buffalo, New York, uniquely positioned as the only independently managed medical innovation facility operating within a single building. Strategic proximity to Kaleida Health's Gates Vascular Institute and the University at Buffalo's Clinical and Translational Research Center enables seamless collaboration for medical device development. The institute's core mission centers on accelerating next-generation vascular medicine technologies through partnerships between physicians, engineers, entrepreneurs, and industry stakeholders. Key service offerings include the i2R (Idea to Reality) Center, which guides medical device development from ideation through FDA submission; regulatory and quality compliance services; clinical training programs; and a 3D Printing Center of Excellence in Health Care specializing in customizable 3D-printed vascular flow models for anatomical visualization and product testing. The institute also operates education and community programs designed to inspire future healthcare professionals and advance vascular medicine innovation.

Shanghai Shifu Testing Technology Service Co., Ltd. is a professional testing and certification consulting firm specializing in electromagnetic compatibility (EMC) testing, EMC remediation, and international regulatory compliance services. The company provides comprehensive technical consultation and testing services for product certification across multiple international standards and markets, including CE (EU), FDA (USA), FCC, UL, IC (Canada), PSE (Japan), CCC/CQC/SRRC (China), and numerous other regional certifications. Services encompass EMC testing and modification, chemical testing, RF testing, environmental reliability testing, safety standard testing (RoHS, REACH), and compliance guidance for electronics, toys, machinery, pressure equipment, building materials, elevators, rail vehicles, and marine products. The firm assists manufacturers in navigating international trade barriers and achieving global market access through expert technical guidance and regulatory pathway development.

Aptar Digital Health, a division of Aptar Pharma and part of AptarGroup, Inc., is a comprehensive digital health solutions provider headquartered in Congers, New York. The company specializes in developing and deploying regulated digital therapeutics, companion mobile applications, and connected drug-delivery systems tailored for pharmaceutical and biotechnology partners globally. Aptar Digital Health operates across 120 countries with 20+ years of digital health leadership, supporting 15+ regulatory approvals and 17+ clinical studies. The platform is ISO 13485 and ISO 27001 certified, MDSAP-compliant, and adheres to HIPAA and GDPR standards. Core offerings include Software as a Medical Device (SaMD), Digital Patient Support Programs (PSPs), Disease Management Platforms, and Real-World Evidence generation services. Therapeutic focus areas encompass oncology, respiratory care, neurology (migraine, multiple sclerosis), immunology, and chronic disease management. The company's integrated platform enables pharmaceutical partners to enhance treatment adherence, optimize patient engagement across the entire treatment journey, and generate actionable clinical insights through connected devices and user community analytics.

Mighty Oak Medical is a commercial-stage medical device development company specializing in patient-specific solutions for complex spinal surgery. Founded in 2011 and based in Englewood, Colorado, the company designs and manufactures advanced surgical planning, guidance, and visualization tools that enhance safety, precision, and efficiency in spine instrumentation procedures. The company's core competencies include AI-driven 3D pre-surgical planning, 3D-printed patient-specific surgical navigation guides, and anatomical bone models. The flagship FIREFLY Pedicle Screw Navigation Guides platform is FDA-cleared and CE-marked, providing surgeons with personalized pre-operative planning, intraoperative guidance, and detailed anatomical analytics to reduce operative time, improve screw placement accuracy, and lower radiation exposure during cervical, thoracolumbar, and pelvic instrumentation. Mighty Oak partners with HP for advanced 3D manufacturing using Multi Jet Fusion technology and with OrthoPediatrics for exclusive distribution in children's hospitals. The company has completed 3,700+ cases, planned 80,000+ screws, earned 9 FDA clearances, and holds 100+ patents worldwide.

Redica Systems is a Quality and Regulatory Intelligence (QRI) software platform serving pharmaceutical, medical device, food, cosmetics, and supplement companies. The company operates a comprehensive AI-driven data analytics cloud that aggregates and analyzes regulatory, inspection, enforcement, post-market, and site data from over 250 global regulatory agencies and standards bodies. The Redica platform unifies data from enterprise systems like Veeva, SAP, Trackwise, and Snowflake to deliver actionable intelligence across quality, regulatory affairs, supply chain, and compliance functions. Core products include Regulatory Intelligence (continuous monitoring of global regulatory changes), Inspection Intelligence (world's largest inspection and enforcement dataset with FDA Form 483 and warning letter analytics), Site Intelligence (supplier network visibility and risk benchmarking), and Post-Market Intelligence (adverse event and recall monitoring). The platform serves over 200 global customers, including major pharmaceutical and medical device manufacturers, enabling inspection readiness, supplier risk mitigation, and accelerated compliance workflows.

Maine Molecular Quality Controls, Inc. (MMQCI) is a specialized manufacturer of quality control reagents and panels for molecular diagnostics laboratories. The company produces high-caliber controls designed to monitor all phases of nucleic acid testing procedures, ensuring accuracy and reliability in diagnostic results. MMQCI's product portfolio includes respiratory pathogen controls (COVID-19, influenza, RSV), tropical fever panels, and gastrointestinal pathogen detection controls. The company is ISO 13485:2016 certified, demonstrating compliance with medical device quality management standards. MMQCI's controls are engineered to support clinical laboratories in meeting best-practice standards and regulatory requirements for molecular testing across viral, bacterial, and parasitic pathogen detection.

TransducerWorks, founded in 2007 and part of the Vermon Group since 2018, is a U.S.-based manufacturer of custom ultrasound transducers, arrays, and probes for medical and industrial applications. The company employs 100+ engineers and manufacturing experts in Pennsylvania and delivers high-performance solutions for OEMs in diagnostics, point-of-care, interventional, veterinary, and innovation-driven medical sectors. TransducerWorks specializes in medical diagnostic probes for radiology, cardiovascular, and OB/GYN imaging, including portable and handheld (POCUS) systems for emergency and ICU use. The company also develops therapeutic ultrasound solutions for neurostimulation, neuromodulation, and targeted drug delivery, spanning focused (HIFU, LIFU) and unfocused (LIPUS) applications at frequencies above 500 kHz. Veterinary ultrasound offerings cover all species with rugged, cost-effective designs compatible with portable or cart systems. TransducerWorks operates under ISO 13485 certification with FDA compliance, RoHS and REACH adherence, ensuring precision, traceability, and regulatory alignment for medical device manufacturers and research institutions.

Hydromer, Inc. is a global B2B provider of surface modification and coating solutions, specializing in hydrophilic polymer research, development, and manufacturing. Founded in 1980 and based in Concord, North Carolina, the company is ISO 9001:2015 certified with over 40 years of expertise in creating innovative polymer-based products for medical devices, industrial plastics, and specialized applications. Hydromer offers a comprehensive portfolio of hydrophilic coatings—including UV-curable and thermal-curable systems—tailored for cardiovascular, gastroenterology, neurovascular, ophthalmology, peripheral vascular, and urological devices. The company provides end-to-end services including custom formulation development, contract coating, R&D services, FDA regulatory support, and technology transfer. With a 98% repeat customer rate and support for over 1,000 medical device customers worldwide, Hydromer delivers lubricious, anti-thrombogenic, and performance-enhanced coatings for catheters, guidewires, balloons, stents, endoscopes, and other interventional and diagnostic devices. Global production and service hubs ensure consistent quality and responsive support across Asia and the Americas.

PatSnap is an AI-driven innovation intelligence platform providing R&D and intellectual property (IP) insights from over 2 billion structured data points covering patents, scientific literature, litigation, and tech sectors. Founded in Singapore and serving 18,000+ organizations globally, PatSnap enables faster innovation (75% faster at 25% less cost) through advanced analytics, patent analysis, competitive intelligence, and design FTO assessments. The platform offers AI agents for IP, engineering, life sciences, and materials domains, with specialized modules including biosequence search (Bio), chemical structure analysis (Chemical), and biopharma intelligence (Synapse). Available as cloud or on-premises deployment, PatSnap supports law firms, life sciences companies, and high-tech enterprises in accelerating decision-making, protecting IP portfolios, and optimizing R&D efficiency.

Chembio Diagnostics, Inc. is a leading developer and manufacturer of rapid point-of-care (POC) diagnostic tests for infectious diseases, headquartered in Hauppauge, New York, with operations in Medford, New York. The company specializes in innovative diagnostic solutions utilizing its proprietary Dual Path Platform (DPP®) technology, which delivers improved sensitivity, multiplexing capabilities, and rapid results from a small sample of fingertip blood. Chembio's product portfolio includes FDA-approved and CLIA-waived assays for HIV, syphilis, Hepatitis C, COVID-19, and emerging infectious disease detection. The company also develops quantitative diagnostics (FastPack® hCG) and is actively advancing diagnostics for typhoid fever and preeclampsia. With 337 employees and approximately $55.3 million in annual revenue, Chembio markets its solutions to medical laboratories, hospitals, government health agencies, NGOs, and retail establishments across the United States and internationally. The company is committed to delivering exceptional, easy-to-use, fast, and accurate diagnostic solutions to enhance health outcomes in infectious disease detection and monitoring.

Vistapath Biosystems is a software-focused medical technology company headquartered in Cambridge, MA. The company develops Sentinel, an end-to-end digital grossing platform designed to modernize pathology laboratory workflows. Sentinel automates and optimizes critical lab processes including tissue specimen grossing, enhancing quality, efficiency, and consistency across commercial laboratories, hospital pathology labs, contract research organizations (CROs), and life sciences companies. The platform leverages artificial intelligence to streamline intraoperative and routine pathology operations. Vistapath collaborates with established diagnostic and pathology partners (PathAI, Gestalt Diagnostics, PathGroup, Freedom Pathology Laboratories) to validate and deploy the Sentinel platform across clinical and research settings. The company targets mid- to large-scale pathology operations seeking digitization and workflow automation. Management includes CEO Tim Spong and VP Sales & Marketing J. Fernando Corredor, who brings over 20 years of medical device industry experience including work with acquired companies (Medtronic, Integra LifeSciences, Samsung) in imaging and AI-driven diagnostics. While regulatory certifications are not explicitly mentioned in available materials, the company's clinical deployment trajectory and partnership with established pathology networks indicate compliance with relevant healthcare software standards.

Radiopharmaceutical Imaging and Dosimetry (Rapid), LLC is a Baltimore-based biotechnology research company founded by Johns Hopkins University experts (Drs. George Sgouros, Eric Frey, and Michael Ghaly). Rapid specializes in quantitative imaging, dosimetry analysis, and precision medicine support for radiopharmaceutical therapies, particularly in oncology. The company provides comprehensive consulting and centralized solutions covering the full workflow from image acquisition protocol development through regulatory support and dosimetry reporting. Services include agent-specific imaging protocol design, centralized vendor-independent SPECT/CT quantitative reconstruction with advanced scatter and crosstalk compensation, and expert dosimetry analysis to optimize patient outcomes and reduce normal organ toxicity. Rapid also develops software solutions, including 3D-RD-S, a SaaS platform for radiopharmaceutical dosimetry calculations and radiobiological response modeling. The company combines 45+ years of NIH-funded research and development experience to standardize and simplify dosimetry for routine precision dosing of radiopharmaceutical therapies.

AdvanBio is a U.S.-based biotechnology research company (subsidiary of Autobio Diagnostics) headquartered in Irvine, California. The company specializes in advancing medical laboratory technology for precision medicine and patient diagnostics. AdvanBio provides comprehensive services including bioanalysis with advanced sample evaluation capabilities, assay development and validation for in vitro diagnostics (IVD) and molecular diagnostics assays, and regulatory consultation to navigate complex global compliance requirements. The company has introduced Autobio/BioYuan quality control products to the U.S. market—essential calibration and verification tools for ensuring diagnostic test accuracy and improving patient care outcomes. With expertise in biomarker development, diagnostic platform integration, and biological molecule analysis, AdvanBio serves laboratory and diagnostic manufacturers seeking innovation, regulatory expertise, and supply chain stability.

Percy Sleep is a contactless, non-video behavioral measurement system designed to scale evidence-based sleep therapy and diagnose sleep disorders without relying on medication. The device uses passive sensors to collect real-time behavioral and environmental data throughout the night while protecting patient privacy. An AI-driven algorithm analyzes this data to help healthcare providers identify factors impacting sleep quality, with results delivered through a provider dashboard for remote monitoring and consultation. Percy addresses a significant clinical need: 35% of the population experiences significant sleep challenges, with particularly high prevalence among autistic individuals (80%). Unlike traditional sleep labs (invasive, time-consuming, unavailable), medication (treats symptoms only), or standard biometric trackers (lacks behavioral insights), Percy enables scalable behavioral sleep therapy by automating data collection and analysis. The platform supports personalized treatment plans, reduces medication reliance, improves patient compliance, and decreases overall healthcare costs—addressing the $100 billion annual economic burden of poor sleep on the US healthcare system.

nRichDX is a biotechnology company specializing in advanced sample preparation systems for liquid biopsy and precision medicine diagnostics. The company's flagship Revolution Sample Prep Platform™ enables high-yield extraction of circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), and circulating tumor cells (CTCs) from multiple biofluids including plasma, whole blood, urine, cerebrospinal fluid, and peritoneal fluid. The Revolution Plus semi-automated instrument processes sample volumes from 1 mL to 100 mL in a single extraction, significantly improving analyte yield compared to traditional spin-column and vacuum-based methods. nRichDX addresses a critical limitation in liquid biopsy workflows—sample preparation sensitivity—through its proprietary nRicher Cartridge technology that eliminates multiple sample transfers and yield-lowering procedures. The company offers a comprehensive portfolio of Revolution Kits optimized for different analytes (cfDNA, cfRNA, cfTNA, CTCs) and sample types, supporting early cancer detection, infectious disease testing, and neurological disease research. nRichDX serves clinical laboratories, academic medical centers, and molecular diagnostics companies requiring sensitive detection of rare circulating biomarkers. The platform integrates with automation partners including Hamilton liquid handlers for fully scalable workflows.

Everex is an Italian engineering company with over 30 years of experience in the design and production of intelligent analysis instruments for in vitro diagnostics (IVD) and biotechnology applications. Specializing in tailor-made solutions, Everex develops diagnostic devices from concept through prototyping to full-scale production. The company leverages advanced technologies including 3D printing (HP Multi Jet Fusion), artificial intelligence, and integrated CAD/CAE/CAM systems to deliver high-performance diagnostic instruments. Key product offerings include the Skylab 752, an automated ELISA system for clinical laboratories, and the Hemo One, a blood analysis device utilizing clinical chemistry techniques. Everex holds ISO 13485:2016, ISO 9001:2015, and ISO 14001:2015 certifications, demonstrating commitment to medical device quality standards. The company serves medical and biotechnology sectors as a development partner for IVD instrument innovation and manufacturing.

Prenosis Inc. is a Chicago-based precision medicine and artificial intelligence company founded in 2014, specializing in AI-powered diagnostics for acute care settings. The company's flagship product, the Sepsis ImmunoScore™, is the first FDA De Novo-authorized AI diagnostic tool for sepsis diagnosis and prediction of adverse outcomes. It integrates seamlessly into hospital electronic medical records and provides real-time clinical decision support by combining biomarker analysis with clinical data. The proprietary Immunix® precision medicine platform captures extensive biomarker and clinical data from acute care patients, enabling the development and real-time deployment of precision medicine tools. This platform has built the world's largest biobank linked to clinical infection data in acute care, encompassing over 138,000 longitudinal specimens and 35,000 patients across 11+ hospitals. Prenosis partners with Roche Diagnostics for distribution through the navify® Algorithm Suite. The company empowers clinicians to move beyond symptom-based diagnoses toward biology-based treatment decisions, improving patient outcomes and reducing hospital costs while supporting quality metrics.

HAI Laboratories, Inc. is an ISO 13485-certified U.S. manufacturer of ophthalmic diagnostic equipment and imaging systems headquartered in Lexington, MA since 1996. The company specializes in clinical, eye bank, and laboratory specular microscopes—the only American manufacturer of these instruments in operation today. HAI produces digital video slit lamps with advanced 3CCD technology for anterior segment imaging, high-resolution endothelial imaging systems for corneal analysis, and custom-configured specular microscopy platforms. The company also develops proprietary image processing and analysis software systems for ophthalmic applications. In addition to diagnostic equipment, HAI manufactures precision ophthalmic microsurgical instruments and motorized microscope stands. Known for user-driven product development and modular system design, HAI offers factory-direct pricing, equipment rentals, professional installation, on-site training, and validation services to eye banks, hospitals, universities, and private clinics worldwide.

Karuna Labs develops KarunaHOME, a neuroscience-based digital therapeutic platform combining proprietary virtual reality neurotechnology with personalized behavioral coaching for chronic pain management and acquired brain injury rehabilitation. The 12-week program addresses multiple pain conditions including low back pain, shoulder pain, upper and lower extremity pain, widespread pain, central pain, and neuropathic pain. The solution is non-pharmacological and non-surgical, employing evidence-based neuroscience principles such as predictive processing, neuroplasticity, active inference, and embodied cognition theory. The platform includes at-home virtual reality equipment paired with remote coaching sessions delivered by pain specialists. KarunaHOME is designed for convenient, flexible use in home settings and emphasizes engagement through gamified rehabilitation experiences. The company targets patients seeking alternatives to opioid-based therapies and surgical interventions. Clinical approach integrates biopsychosocial treatment frameworks with exposure therapy and fear-avoidance reduction strategies.

ScandiDos is a Swedish medical device and software manufacturer specializing in quality assurance and measurement systems for radiotherapy treatment planning and delivery. The company provides innovative solutions that enable cancer clinics to verify and validate radiation dose distributions, ensuring safe and accurate treatment administration. Their Delta4 Phantom+ system combines advanced dosimetry hardware with computational software to help radiation oncologists and medical physicists confirm that cancer patients receive precisely targeted radiation therapy. ScandiDos solutions improve treatment confidence, enhance clinical workflows, and support the individualization of radiotherapy protocols across hospital networks.

Medix Biochemica is a Finnish global leader in developing and manufacturing critical raw materials for the in vitro diagnostics (IVD) industry. Established in 1985, the company specializes in supplying over 5,000 high-quality products including monoclonal and polyclonal antibodies, recombinant antigens, proteins, enzymes, molecular reagents, and processed biologicals. With operations across Europe (Finland, France, Germany), North America (USA), and China, and approximately 293 employees, Medix Biochemica derives over 90% of revenue from international exports. The company holds ISO 13485 certification and FDA QSR compliance, supporting over 10 billion laboratory tests worldwide. Beyond product supply, Medix Biochemica offers custom services including antibody development, contract manufacturing, bioassay development, and specialized plasma processing tailored to diagnostic assay manufacturers' needs.